Vertex Pharmaceuticals Incorporated Common Stock VRTX
i
Market dataready · fetched 2026-11-07T01:43:45.728Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:55:13.083419959Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T01:43:45.260028+00:00
Vertex Pharmaceuticals Incorporated Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 571.06 | 33.7% | 4.7% | 519.54 | 48.3% | 6.0% |
| 25Δ | 567.20 | 34.8% | 4.2% | |||
| 30Δ | 562.98 | 34.5% | 3.6% | 534.33 | 37.6% | 3.5% |
| 35Δ | 558.28 | 31.9% | 2.9% | 538.56 | 36.3% | 2.9% |
| 40Δ | 555.16 | 32.1% | 2.5% | 542.13 | 36.5% | 2.6% |
| 45Δ | 552.27 | 34.0% | 2.3% | 545.65 | 36.2% | 2.2% |
| 50Δ | 549.02 | 34.3% | 2.0% | 549.10 | 36.2% | 1.9% |
| 55Δ | 545.78 | 34.2% | 1.7% | 552.59 | 36.3% | 1.6% |
| 60Δ | 542.59 | 33.5% | 1.4% | 556.13 | 36.3% | 1.3% |
| 65Δ | 539.09 | 34.2% | 1.2% | 559.84 | 36.3% | 1.1% |
| 70Δ | 535.57 | 34.2% | 1.0% | 563.40 | 35.5% | 0.8% |
| 75Δ | 531.57 | 34.6% | 0.8% | 568.08 | 36.2% | 0.7% |
| 80Δ | 526.70 | 35.7% | 0.6% | 573.65 | 37.4% | 0.5% |
20Δ
- Pseudo strike
- 571.06
- IV
- 33.7%
- B/E move
- 4.7%
- Pseudo strike
- 519.54
- IV
- 48.3%
- B/E move
- 6.0%
25Δ
- Pseudo strike
- 567.20
- IV
- 34.8%
- B/E move
- 4.2%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 562.98
- IV
- 34.5%
- B/E move
- 3.6%
- Pseudo strike
- 534.33
- IV
- 37.6%
- B/E move
- 3.5%
35Δ
- Pseudo strike
- 558.28
- IV
- 31.9%
- B/E move
- 2.9%
- Pseudo strike
- 538.56
- IV
- 36.3%
- B/E move
- 2.9%
40Δ
- Pseudo strike
- 555.16
- IV
- 32.1%
- B/E move
- 2.5%
- Pseudo strike
- 542.13
- IV
- 36.5%
- B/E move
- 2.6%
45Δ
- Pseudo strike
- 552.27
- IV
- 34.0%
- B/E move
- 2.3%
- Pseudo strike
- 545.65
- IV
- 36.2%
- B/E move
- 2.2%
50Δ
- Pseudo strike
- 549.02
- IV
- 34.3%
- B/E move
- 2.0%
- Pseudo strike
- 549.10
- IV
- 36.2%
- B/E move
- 1.9%
55Δ
- Pseudo strike
- 545.78
- IV
- 34.2%
- B/E move
- 1.7%
- Pseudo strike
- 552.59
- IV
- 36.3%
- B/E move
- 1.6%
60Δ
- Pseudo strike
- 542.59
- IV
- 33.5%
- B/E move
- 1.4%
- Pseudo strike
- 556.13
- IV
- 36.3%
- B/E move
- 1.3%
65Δ
- Pseudo strike
- 539.09
- IV
- 34.2%
- B/E move
- 1.2%
- Pseudo strike
- 559.84
- IV
- 36.3%
- B/E move
- 1.1%
70Δ
- Pseudo strike
- 535.57
- IV
- 34.2%
- B/E move
- 1.0%
- Pseudo strike
- 563.40
- IV
- 35.5%
- B/E move
- 0.8%
75Δ
- Pseudo strike
- 531.57
- IV
- 34.6%
- B/E move
- 0.8%
- Pseudo strike
- 568.08
- IV
- 36.2%
- B/E move
- 0.7%
80Δ
- Pseudo strike
- 526.70
- IV
- 35.7%
- B/E move
- 0.6%
- Pseudo strike
- 573.65
- IV
- 37.4%
- B/E move
- 0.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 26.76% | |
| 22.96% | |
| 23.23% | |
| 29.37% | |
| 23.03% | |
| 26.12% | |
| 26.08% | |
| 29.66% | |
| 31.24% | |
| 28.55% | |
| 29.02% | |
| 26.82% | |
| 28.43% | |
| 27.23% | |
| 24.61% | |
| 28.07% | |
| 27.56% | |
| 27.78% | |
| 29.32% | |
| 26.70% | |
| 31.18% | |
| 31.61% | |
| 34.28% | |
| 28.08% | |
| 31.31% | |
| 31.23% | |
| 30.67% | |
| 30.54% | |
| 27.90% | |
| 29.23% | |
| 27.83% | |
| 26.79% | |
| 28.74% | |
| 25.15% | |
| 29.12% | |
| 27.52% | |
| 29.36% | |
| 28.71% | |
| 26.60% | |
| 26.70% | |
| 26.73% | |
| 28.23% | |
| 30.49% | |
| 27.10% | |
| 28.69% | |
| 30.02% | |
| 31.69% | |
| 32.15% | |
| 31.97% | |
| 33.50% | |
| 33.10% | |
| 35.50% | |
| 38.04% | |
| 37.09% | |
| 38.89% | |
| 39.59% | |
| 41.26% | |
| 42.69% | |
| 42.34% |
Biotechnology
VSTM
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in…
More →VYGR
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered…
More →WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in…
More →WVE
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development…
More →XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in…
More →XENE
Description unavailable
More →